Insight Molecular Diagnostics Nears FDA Submission for GraftAssureDx with Key Milestones
Event summary
- Completed three-site reproducibility study at Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health in February 2026.
- Collected sufficient clinical samples for FDA submission, with ongoing patient biopsies for validation.
- Achieved ISO 13485 certification on February 26, 2026, enabling U.K. and E.U. regulatory submissions.
- Approximately 340 of 12,000 required instrument and assay cycles remain for FDA submission package.
The big picture
Insight Molecular Diagnostics is advancing its GraftAssureDx test kit toward FDA submission, positioning itself to disrupt the transplant rejection testing market with localized, molecular diagnostic solutions. The completion of key milestones, including clinical trials and ISO certification, underscores the company's strategic push toward regulatory approval and global market expansion. The roughly $2 billion addressable market for regulated transplant rejection testing presents a significant opportunity for iMDx to expand access to organ health testing for kidney transplant patients.
What we're watching
- Regulatory Timing
- Whether the remaining 340 instrument and assay cycles will be completed on schedule to meet FDA submission deadlines.
- Market Disruption
- How the localized testing capability of GraftAssureDx will impact the $2 billion-plus transplant rejection testing market.
- Global Expansion
- The pace at which ISO 13485 certification will facilitate regulatory submissions in the U.K. and E.U. during 2026.
Related topics